Scotiabank reiterated their outperform rating on shares of Trilogy International Partners (TSE:TRL) in a report published on Thursday morning. Scotiabank currently has a C$9.50 price target on the specialty pharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. TD Securities increased their price target on Trilogy International Partners from C$9.50 to C$10.00 and gave the company a buy rating in a report on Tuesday, October 24th. Royal Bank Of Canada increased their price objective on Trilogy International Partners from C$9.00 to C$11.00 and gave the company an outperform rating in a research report on Monday, November 13th.

Trilogy International Partners (TSE TRL) opened at C$5.36 on Thursday. Trilogy International Partners has a twelve month low of C$5.19 and a twelve month high of C$10.02.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at

Trilogy International Partners Company Profile

Trilogy International Partners Inc, formerly Alignvest Acquisition Corporation, is a Canada-based wireless telecommunications operator. The Company provides wireless communications services through its subsidiaries in New Zealand and Bolivia. Its subsidiaries include Viva and 2degrees. Viva provides voice and a range of data services to its mobile customers over its third generation (3G)-enabled global system for mobile communications (GSM) and fourth generation (4G) long term evolution (LTE) networks.

Receive News & Ratings for Trilogy International Partners Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trilogy International Partners Inc and related companies with's FREE daily email newsletter.